Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Oki

Showing results (51-60 of 164) with videos related to

Pageof 17
Sort By:
Advances in Radiation Oncology|September 12, 2018
Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphomaChelsea C Pinnix, Jinhai Huo, Sarah A Milgrom, et al.
Leukemia & Lymphoma|October 13, 2011
Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphomaYasuhiro Oki, Amanda Copeland, Jorge Romaguera, et al.
Haematologica|September 2, 2017
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trialYasuhiro Oki, Kevin R Kelly, Ian Flinn, et al.
Clinical Lymphoma & Myeloma|December 3, 2009
Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphomaHarumi Kato, Hirofumi Taji, Michinori Ogura, et al.
Annals of Hematology|January 9, 2019
Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?Dai Chihara, Yasuhiro Oki, Michelle A Fanale, et al.
British Journal of Haematology|July 7, 2018
Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvementDai Chihara, Yasuhiro Oki, Michelle A Fanale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomasDavid J Stewart, Jean-Pierre Issa, Razelle Kurzrock, et al.
European Journal of Haematology|March 27, 2015
Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutationJie Peng, Zhuang Zuo, Bin Fu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 23, 2018
MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomasWenting Huang, L Jeffrey Medeiros, Pei Lin, et al.
British Journal of Haematology|April 18, 2013
Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphomaYasuhiro Oki, Anas Younes, Amanda Copeland, et al.
Pageof 17

Showing results (51-60 of 164) with videos related to

Sort By:
Pageof 17
Advances in Radiation Oncology|September 12, 2018
Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphomaChelsea C Pinnix, Jinhai Huo, Sarah A Milgrom, et al.
Leukemia & Lymphoma|October 13, 2011
Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphomaYasuhiro Oki, Amanda Copeland, Jorge Romaguera, et al.
Haematologica|September 2, 2017
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trialYasuhiro Oki, Kevin R Kelly, Ian Flinn, et al.
Clinical Lymphoma & Myeloma|December 3, 2009
Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphomaHarumi Kato, Hirofumi Taji, Michinori Ogura, et al.
Annals of Hematology|January 9, 2019
Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?Dai Chihara, Yasuhiro Oki, Michelle A Fanale, et al.
British Journal of Haematology|July 7, 2018
Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvementDai Chihara, Yasuhiro Oki, Michelle A Fanale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomasDavid J Stewart, Jean-Pierre Issa, Razelle Kurzrock, et al.
European Journal of Haematology|March 27, 2015
Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutationJie Peng, Zhuang Zuo, Bin Fu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 23, 2018
MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomasWenting Huang, L Jeffrey Medeiros, Pei Lin, et al.
British Journal of Haematology|April 18, 2013
Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphomaYasuhiro Oki, Anas Younes, Amanda Copeland, et al.
Pageof 17